It is Africa's first of three planned projects on the continent and aims to produce treatments against Covid-19 and other diseases by early 2024. "BioNTech is researching and developing vaccines and medicines to prevent malaria, tuberculosis and HIV. â€œThese diseases are major causes of mortality on the African continent. We've partnered with the Bill and Melinda Gates Foundation to develop the tuberculosis and HIV vaccines and we are developing malaria vaccines. ", said Sahin. Kagame called the project "grounbreaking" and said his country worked to attract biopharmaceutical researchers in the manufacturing sector. Production will include vaccines against Covid, but also pioneering treatments currently in development against malaria, tuberculosis and HIV, diseases that are ravaging Africa. Human trials of a BioNTech malaria vaccine using mRNA technology are expected to begin in late 2022. Africa is the world's least vaccinated continent against Covid-19. Less than 20% of its 1.2 billion population have received two doses of vaccine. --AfricaNews--  